SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Durata Therapeutics, Inc. Completes Target Enrollment in Phase 3 DISCOVER 2 Clinical Trial Comparing Dalbavancin to Vancomycin and Linezolid in ABSSSI Patients